Lipid nanoparticles (LNPs) have emerged as a revolutionary delivery system for mRNA vaccines. Recent research has shown that COVID-19 mRNA-LNP vaccines can also enhance cancer immunotherapy. However, further development of this application in the US is hindered by substantial funding cuts and safety concerns raised by the government. This situation could also impact the development and uptake of LNP-based medicinal products in Europe. To promote continued research in this area, European initiatives on “advanced materials” could be explored. 

The future of mRNA-LNP platforms in cancer therapy 

Lipid nanoparticles (LNP) have become widely known as a delivery system for mRNA vaccines, including those developed for COVID-19 mRNA vaccines. Recent research indicates that mRNA-LNP platforms may also have promising applications in cancer treatment. However, this application is facing increasing uncertainty as the US administration is reducing funding for mRNA vaccine research. 

Enhancing immune responses in tumours 

Immune checkpoint inhibitors (ICIs) are a well-known class of cancer immunotherapy drugs that improve survival for many cancer patients. These therapies work by releasing the brakes on the immune system, enabling it to recognise and eliminate cancer cells. However, ‘immune-cold’ tumours that lack immune-activating antigens often respond poorly to checkpoint inhibitors. A significant challenge in oncology is finding ways to transform these poorly responsive tumours into ones the immune system can recognise and attack. Personalised mRNA cancer vaccines can make immune-cold tumours more responsive to ICIs, yet their production is complex and time-consuming. 

An unexpected advantage of mRNA-LNP technology  

Recent research shows that COVID-19 mRNA-LNP vaccines can sensitise tumours to ICIs. https://www.nature.com/articles/d41586-025-03432-7https://www.nature.com/articles/d41586-025-03411-yhttps://www.the-scientist.com/covid-vaccines-boosted-survival-outcomes-in-cancer-patients-73637The vaccine acts as an alarm signal that activates the immune system and helps it to recognise and eliminate cancer cells when combined with immunotherapy. This effect was particularly evident in animal models with "immune-cold" tumours. 

Furthermore, patients with lung cancer and adenoma who received a COVID-19 mRNA-LNP vaccine within 100 days of starting ICI treatment showed improved overall survival and progression-free survival compared with patients who had not. Similar benefits were not seen with other vaccines, like influenza or pneumococcal vaccines, suggesting that the effect is not simply due to general immune stimulation. 

Innovative applications of mRNA-LNP technology 

The proposed explanation lies in the specific combination of mRNA and LNPs. When mRNA is encapsulated in LNPs, it forms larger, more complex structures that can trigger a stronger immune response than free mRNA alone. The findings suggest that mRNA-LNP vaccines may have broader applications beyond vaccinations. They seem to act as powerful immune modulators, making tumours more responsive to immunotherapy without specifically targeting tumour antigens. This opens new possibilities for using mRNA-LNP technology in cancer treatment, especially as a fast, universal immune modulator. A clinical trial is being conducted in the US to test whether these findings can be translated into clinical practice. The results of this trial are expected in 2035. 

Shift in US funding threatens mRNA vaccine innovation 

At the same time, the scientific momentum is facing challenges due to recent developments in the United States. The US government has decided to cut $500 million in funding for mRNA-LNP vaccine research.  This marks a major shift from the US’s previous role as a central driver of mRNA innovation through programs such as Operation Warp Speed, which enabled the rapid development of COVID-19 vaccines.   

In addition to these funding cuts, the current US administration is questioning the safety of mRNA-LNP vaccines, which were once seen as lifesaving during the COVID-19 pandemic. This scepticism undermines public confidence in mRNA technologies and contributes to an increasingly uncertain investment climate. As a result, companies such as Moderna, Pfizer, Sanofi Pasteur, and AstraZeneca are excluded from new funding opportunities, leading to a renewed focus on older vaccine technologies, such as whole-virus vaccines.  

Reflections by RIVM  

The recent funding cut in the US not only affects American research but may also hinder innovation on LNP-based medicinal products in Europe. Vaccine developers operating in Europe, such as Moderna and Pfizer, rely heavily on funding from the US. While the budget cut primarily targets mRNA vaccine research, it may also slow down the clinical translation of innovative applications of mRNA LNP platforms, like enhancing cancer immunotherapy.  

It is important to assess the impact of these changes on mRNA-LNP vaccines and to seek alternative ways to secure and stimulate research into the positive effects of LNP-based medicinal products. 

One possible approach is to align with European initiatives for Advanced Materials (AdMa), as LNP-mRNA platforms would fall within the OECD working description of AdMa. Last year, the Technology Council for Advanced Materials acknowledged the strategic opportunity that advanced materials offer for personalised medicine and for boosting Europe’s position in the medical device and nanomedicine markets.  

By proactively engaging with these European initiatives and seeking alternative funding sources, Europe can help safeguard continued innovation in lipid nanoparticle-based medicinal products, ensuring that the potential benefits of mRNA-LNP technologies for infectious disease and cancer treatment and gene therapies remain within reach.